Peptide audit readiness in 2026
A field guide for 503B outsourcing facilities, 503A pharmacies, and peptide developers facing sustained FDA scrutiny.
What’s inside
An 11-page field guide for 503B outsourcing facilities, 503A pharmacies, and peptide developers. Fill out the form to download the PDF.
- How the 2025 to 2026 enforcement wave changed audit exposure for peptide operations
- The regulatory map: 503A, 503B, Category 1 and 2 bulk substances, and where peptides sit today
- What GLP-1 enforcement signals for every other peptide
- The seven audit surfaces investigators examine
- Where Form 483 observations most often land
- The cPC audit framework and a 90-day readiness sprint plan
Get the PDF
We use your details to deliver the white paper and, if you opt in, occasional updates. This guide is educational and is not legal advice.
